BIO3 Share Price

Open 19.81 Change Price %
High 19.90 1 Day 0.20 1.02
Low 19.65 1 Week -0.22 -1.10
Close 19.82 1 Month 1.79 9.93
Volume 286377 1 Year 3.83 23.95
52 Week High 20.30
52 Week Low 12.02
BIO3 Important Levels
Resistance 2 20.05
Resistance 1 19.96
Pivot 19.79
Support 1 19.68
Support 2 19.59
ETR Germany Most Active Stocks
CBK 9.10 9.38%
CBK 9.10 9.38%
DBK 16.99 9.19%
DBK 16.99 9.19%
EOAN 7.26 1.26%
EOAN 7.26 1.26%
DTE 16.36 2.70%
DTE 16.36 2.70%
DTE 16.36 2.70%
DTE 16.36 2.70%
More..
ETR Germany Top Gainers Stocks
ARO 0.02 100.00%
ARO 0.02 100.00%
S9H 0.16 45.45%
TLI 0.17 21.43%
TLI 0.17 21.43%
E8X 0.80 14.29%
5M71 39.00 13.70%
A8A 6.85 13.04%
ZSB 0.10 11.11%
SGE 50.70 9.86%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
2GB 21.70 -8.82%
CR8 8.15 -8.53%
EDGA 3.35 -8.22%
EDG 3.36 -7.44%
EDG 3.36 -7.44%
More..

Biotest AG (ETR: BIO3)

BIO3 Technical Analysis 5
As on 24th Apr 2017 BIO3 Share Price closed @ 19.82 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 14.70 & Strong Buy for SHORT-TERM with Stoploss of 18.26 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO3 Target for April
1st Target up-side 19.23
2nd Target up-side 20.19
3rd Target up-side 21.14
1st Target down-side 16.51
2nd Target down-side 15.55
3rd Target down-side 14.6
BIO3 Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO3 Address
BIO3
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO3 Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO3 ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO3 Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.